

Amendments to the Specification:

Please replace the paragraph beginning at page 12, line 23 with the following amended paragraph:

The cancer vaccine used in various embodiments of the instant invention may be selected from any DC-based cancer vaccine, and can be administered by routine methods. The DC may be autologous tumor antigen-presented DC that are “primed” ex vivo by conventional methods; for instance, the DC may be loaded with HLA-eluted peptides from cultured tumor cells or autologous tumor lysate. Alternatively, the DC may be delivered in an “unprimed” state and essentially primed in vivo, as described in U.S. patent application Ser. No. 10/251,148, filed Sep. 20, 2002, published as US 2004/0057935, the disclosure of which is incorporated by reference herein in its entirety. Use of “unprimed” DC may be particularly advantageous in instances where a tumor is surgically inoperable, where surgery is otherwise undesirable, or where no portion of the tumor can be retrieved for priming DC ex vivo against the tumor.